This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Cabergoline

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

This is a long-acting D2 dopamine receptor agonist which may be used for the treatment of hyperprolactinaemia.

The long half-life of cabergoline means that it need only be taken once or twice a week in contrast to the twice daily dosage for bromocriptine.

There are fewer unwanted effects, such as nausea and vomiting, in patients taking cabergoline as compared to patients taking bromocriptine.

Treatment with cabergoline has been associated with the onset of fibrotic cardiac vulvopathy:

  • trials suggest that using ergot-derived dopamine agonists such as cabergoline in the treatment of Parkinson's disease is associated with an increased risk of valvular heart disease (1)
    • population studies of patients with Parkinson's disease compared with non-parkinsonian controls have reported that pergolide and cabergoline have a similar risk of inducing fibrotic changes in cardiac valve leaflets. The fibrotic changes cause thickening, retraction, and stiffening of valves, which result in incomplete leaflet coaptation and clinically significant regurgitation, and have necessitated surgical valve replacement in some patients
  • however cabergoline at doses sufficient to suppress hyperprolactinaemia for a period of 3-4 years were not associated with an increased risk of clinically significant valvular regurgitation (2)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.